"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
| Descriptor ID |
D018572
|
| MeSH Number(s) |
E01.789.200 E05.318.740.998.300 N05.715.360.750.795.300 N06.850.520.830.998.300
|
| Concept/Terms |
Disease-Free Survival- Disease-Free Survival
- Disease Free Survival
- Event-Free Survival
- Event Free Survival
- Event-Free Survivals
- Survival, Event-Free
- Survivals, Event-Free
- Survival, Disease-Free
- Disease-Free Survivals
- Survival, Disease Free
- Survivals, Disease-Free
Progression-Free Survival- Progression-Free Survival
- Progression Free Survival
- Progression-Free Survivals
- Survival, Progression-Free
- Survivals, Progression-Free
|
Below are MeSH descriptors whose meaning is more general than "Disease-Free Survival".
Below are MeSH descriptors whose meaning is more specific than "Disease-Free Survival".
This graph shows the total number of publications written about "Disease-Free Survival" by people in this website by year, and whether "Disease-Free Survival" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 4 | 4 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 9 | 9 |
| 2014 | 0 | 6 | 6 |
| 2015 | 0 | 18 | 18 |
| 2016 | 0 | 28 | 28 |
| 2017 | 1 | 346 | 347 |
| 2018 | 1 | 251 | 252 |
| 2019 | 0 | 77 | 77 |
| 2020 | 0 | 12 | 12 |
| 2021 | 0 | 13 | 13 |
To return to the timeline, click here.
Below are the most recent publications written about "Disease-Free Survival" by people in Profiles.
-
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. J Clin Invest. 2021 10 01; 131(19).
-
In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. J Clin Invest. 2021 10 01; 131(19).
-
Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality. J Clin Invest. 2021 10 01; 131(19).
-
Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients. Signal Transduct Target Ther. 2021 08 17; 6(1):304.
-
Clinical Characteristics and Outcomes of COVID-19 Patients with Overweight and Obesity: Turkish Nationwide Cohort Study (TurCObesity). Exp Clin Endocrinol Diabetes. 2022 Feb; 130(2):115-124.
-
Does delaying curative surgery for colorectal cancer influence long-term disease-free survival? A cohort study. Langenbecks Arch Surg. 2021 Nov; 406(7):2383-2390.
-
The Role of Obesity in the Immunopathogenesis of COVID-19 Respiratory Disease and Critical Illness. Am J Respir Cell Mol Biol. 2021 07; 65(1):13-21.
-
Improved outcomes over time for adult COVID-19 patients with acute respiratory distress syndrome or acute respiratory failure. PLoS One. 2021; 16(6):e0253767.
-
Relation of Serum Copper Status to Survival in COVID-19. Nutrients. 2021 May 31; 13(6).
-
The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all? Cytokine. 2021 08; 144:155593.